



A

Note:
Points towards higher hazard




B



	Median OS
Metastatic disease at diagnosis* (n= 276)	6.4 years
Primary disease only at diagnosis (n=891)	13.6 years
P value	<0.0001
Hazard Ratio	3.075

*This group represents an easily defined group that is most similar to published results for metastatic imatinib trials. Patients less than 18 years old at diagnosis were excluded.

C



	Median OS
Later had a recurrence* (n= 487)	11.7 years
No recurrence, regular updates (n=205)	Undefined
P value	<0.0001
Hazard Ratio	2.623

Both groups exclude patients diagnosed below the age of 18.
*This group presented with primary disease only and later had a recurrence.